Novacyt Trading Update

Novacyt trading update Paris, France and Camberley, UK – 24 December 2018 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics products, on the 11 December announced its decision to sell the NOVAprep® business unit. As a result, the Company confirms that NOVAprep® will be treated as a discontinued operation under

Visit Page

Point sur l’activité

Novacyt Point sur l’activité Paris, France et Camberley, UK – le 24 décembre 2018 – Novacyt (EURONEXT GROWTH : ALNOV ; AIM : NCYT), spécialiste international du diagnostic clinique, a annoncé le 11 décembre sa décision de céder la division NOVAprep®. Le Groupe confirme que cette division sera traitée comptablement en normes IFRS comme activité

Visit Page

Novacyt lance deux nouveaux kits de diagnostic moléculaire marqués CE-IVD

Novacyt launches two new molecular CE Mark assays Premiers d’un portefeuille en croissance de tests pour le suivi des patients en post-transplantation et immunodéprimés

Visit Page

Novacyt announces update on strategic review of non-core assets

Novacyt announces update on strategic review of non-core assets NOVAprep® and clinical laboratory enter formal sales process Novacyt to enhance focus on core profitable diagnostic products business

Visit Page

INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET ACTIONS COMPOSANT LE CAPITAL SOCIAL

Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers http://novacyt.com/wp-content/uploads/2018/12/NOVACYT_CP_Droits-de-vote_2018-Dec.pdf

Visit Page

Réalisation d’une importante commande d’instruments de diagnostic moléculaire q16 Croissance dans le marché du diagnostic clinique dans un marché chinois en forte croissance

Novacyt q16 en Chine Paris, France et Camberley, UK – le 6 décembre 2018 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), spécialiste international du diagnostic clinique, annonce aujourd’hui qu’il a reçu une autre commande importante pour les instruments de diagnostic moléculaire q16 de Primerdesign d’un nouveau client sur le marché chinois en forte croissance. La

Visit Page

Completion of substantial q16 molecular diagnostics order expands clinical diagnostic reach in fast growing Chinese market

Novacyt q16 order in China Paris, France and Camberley, UK – 6th December 2018 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces it has received another substantial order for Primerdesign’s q16 molecular instruments from a new customer within the fast growing Chinese market. The order for 100 molecular

Visit Page

Liquidity Agreement Monthly Update and Total Voting Rights

PParis, France and Camberley, UK – 3 December 2018 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces its monthly update in relation to ordinary shares traded under its ongoing liquidity agreement with Invest Securities SA (the “Liquidity Agreement”). The Liquidity Agreement is governed by French law and is further summarised

Visit Page

The following announcement replaces the announcement released on 30 May 2018 at 18:30 (UK time) under RNS number 7508P.

Replacement Announcement – Novacyt 30-11-18

Visit Page